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We and others have identified CD73 as a new cancer target. I hereafter discuss that targeted blockade of CD73 has the
effect of a “double-edge sword,” able on the one hand to rescue endogenous adaptive anti-tumor immune responses,
and on the other hand, inhibit the metastatic potential of tumor cells.
We have recently described a new strategy
for breaking immune tolerance to cancer
and prevent metastasis: by targeted blockade
of CD73, the ecto-enzyme responsible for
the hydrolysis of extracellular adenosine
monophosphate (AMP) to adenosine.
1,2
Controlled release of triphosphate (ATP)
andactivation ofpurinergicreceptors isnow
well-recognized as a ubiquitous means of
intercellular communication that regulate
key physiological functions such as neuro-
transmission, renal tubule-glomerular feed-
back, bone remodelling, ectopic tissue
calcification, endothelial permeability and
immune responses.
3 In the immune system,
extracellular ATP acts as a “find-me signal”
that guidesphagocytesto inflammatory sites
and promotes clearance of apoptotic cells.
Extracellular ATP also acts as a co-activator
of the NLRP3 inflammasome and a trigger
of adaptive anti-tumor immunity, a mech-
anism essential to the therapeutic activity of
certain chemotherapeutic drugs.
4 In con-
trast to extracellular ATP, extracellular
adenosine is a potent immunosuppressor.
The effects of extracellular adenosine on
tumor immune surveillance was first
revealed by Ohta et al.,
5 who demonstrated
that transcriptional silencing of A2A aden-
osine receptors in T cells enhances their
anti-tumor function in vivo.
Glycosyl-phosphatidylinositol-anchored
CD73 is generally considered as the rate-
limiting enzyme in the generation of extra-
cellular adenosine.
3 CD73 is constitutively
expressed at high levels in various types of
cancers. We have recently set out to
elucidate CD73’s role in tumor immune
evasion and metastasis and assess the
activity of CD73-targeted therapy. In our
first study, we injected immunocompetent
and immunodeficient mice with pro-
metastatic mouse breast tumor cells and
treated the animals with anti-CD73 mAb.
1
We observed that inhibition of primary
tumor growth with anti-CD73 mAb was
dependent on an adaptive immune
response, while suppression of lung meta-
stasis was maintained in immunodeficient
mice. This raised the possibility that
CD73 intrinsically modulates tumor cell
migration. Our in vitro studies revealed
that tumor-derived CD73 promoted
tumor cell chemotaxis via activation of
A2B adenosine receptors.
1
In addition of being expressed on various
tumor cells, CD73 is expressed on endothe-
lial cells, mesenchymal stem cells, Foxp3
+ T
regulatory cells (Tregs) and subsets of
leukocytes that form the tumor stroma.
This suggests that non-transformed stromal
cells may help tumor cells evade immuno-
surveillance through the production of
extracellular adenosine. To address this
question, we recently investigated the role
of host-derived CD73 in tumor immune
evasion.
2 Our work revealed that: (1)
CD73
-deficient mice are resistant to the
growth of immunogenic tumors in a CD8
+
Tcell-dependentmanner;(2)hematopoietic
and non-hematopoietic CD73 expression
each promote tumor immune escape in a
non-redundant manner; (3) CD73 expres-
sion on Foxp3
+ Tregs is a key component
in the pro-tumorigenic effect of Tregs; and
(4) non-hematopoietic expression of CD73,
presumably on endothelial cells, enhances
tumor cell metastasis to the lungs.
Since our initial report, other groups
have now demonstrated the anti-tumor
activity of targeted CD73 blockade. Jin
et al.
6 demonstrated the therapeutic effect
of CD73 inhibition in a mouse model of
ovarian cancer. The same group also
recently demonstrated that CD73-defi-
cient mice have increased CD8-dependent
anti-tumor immunity and that non-
hematopoietic and hematopoietic expres-
sion of CD73 promotes tumor growth in
mice.
7 In their latter study, the authors
demonstrated that tumor-bearing CD73-
deficient mice have enhanced homing of
tumor antigen-specific T cells to draining
lymph nodes and tumors. The authors
proposed that CD73-dependent extracel-
lular adenosine limits tumor homing of
tumor-specific T cells via the activation of
A2B adenosine receptors. Yegutkin et al.
8
also recently reported that CD73-deficient
mice have increased anti-tumor immunity.
Taken together, these studies provide
good evidence that targeting CD73 can
induce anti-tumor activity in mice.
Nevertheless, additional experiments are
needed before translating these findings
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into the clinic. First, extensive documenta-
tion of CD73 expression in various types
of human cancers is needed. Second,
evidence that targeting human CD73 with
a therapeutic mAb induces anti-tumor
activity is still pending. Third, in depth
analysis of anti-CD73 mAb therapy mech-
anism-of-action is required. Finally, evalu-
ation of the potential toxicities that may be
associated with CD73 blockade is critical.
CD73 is involved in several physiological
systems and this could potentially limit
anti-CD73 therapy. Studies in CD73-
deficient mice have shown that CD73 is
important for platelet aggregation and to
protect the heart, kidney and lungs from
ischemia.
9 Notably, a recent study iden-
tified mutations in the CD73 gene result-
ing in a non-functional protein and the
development of symptomatic arterial and
joint calcification in humans,
10 a patho-
logy associated with an excess risk of
cardiovascular events. The increase in
ectopic tissue calcification associated with
a non-functional CD73 protein was found
to be dependent on an increase in tissue-
nonspecific alkaline phosphatase (TNAP).
Therefore, anti-CD73 mAb therapy could
theoretically be combined with inhibitors
of TNAP such as bisphosphonates or
lansoprazole in order to prevent the risk
of arterial calcification.
In conclusion, our recent work revealed
that CD73 expression on tumor cells,
non-hematopoietic and hematopoietic
host cells, including Foxp3
+ Tregs,
potently suppresse adaptive anti-tumor
immune responses. We also observed that
CD73 expression on non-hematopoietic
host cells—possibly endothelial cells—
enhances tumor cell metastasis to the
lungs. These findings, now validated by
other independent groups, strongly suggest
that CD73 may be targeted at multiple
levels to induce anti-cancer effects.
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Table 1. Summary of identified immunosuppressive and pro-metastatic effects of CD73
Immunosuppressive effects Pro-metastatic effects
CD73 on tumor cells Inhibits the function of tumor-reactive CD8+ T cells
via A2A adenosine receptors.
Enhances tumor cell invasion; enhances tumor
cell chemotaxis via A2B adenosine receptors.
CD73 on Foxp3+ Tregs Promotes tumor growth, presumably via inhibition
of tumor-reactive T cells.
n/d
CD73 on endothelial cells Blocks tumor homing of tumor-reactive T cells
via A2B adenosine receptors.
Promotes lung metastasis of intravenously
injected tumor cells.
n/d: not determined
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